RxSight, Inc.

RxSight, Inc. is a commercial-stage medical technology company focused on delivering high-quality customized vision to patients after cataract surgery. The company's core offering is the proprietary RxSight Light Adjustable Lens system, which is the first and only commercially available premium cataract technology allowing doctors to customize and optimize visual acuity post-surgery. This system includes the RxSight Light Adjustable Lens (LAL/LAL+), the RxSight Light Delivery Device (LDD), and associated accessories. The LAL is a premium intraocular lens (IOL) made from a proprietary silicone-based photosensitive material. This material changes refractive power when exposed to specific ultraviolet (UV) light patterns generated by the LDD. The RxSight system aims to overcome limitations of conventional premium IOL technologies by offering a more precise and adaptable method for achieving desired visual outcomes. Unlike conventional premium IOLs, which require patients to select visual priorities before surgery and rely on preoperative measurements, the RxSight system allows surgeons to implant the LAL, determine refractive error several weeks after surgery with patient input, and then use the LDD to modify the LAL for precise visual correction. This process enables patients to iterate their final vision characteristics through customized post-surgical adjustments. A cataract is defined as the loss of transparency in the eye's natural lens, leading to blurry or hazy vision and potential blindness.